Tag

Your search for Access to therapy returned 18 results.


Exclusive HCV Interview: Julio Gutierrez, MD

So my first question is what do you see as the biggest challenges associated with the hepatitis C epidemic in the U.S.? JULIO GUTIERREZ: There are three main challenges currently associated with eradicating hepatitis C in the United States: Most patients in the US are still not receiving care for their hepatitis C infection. In order to cure HCV in these ...

Read More


Exclusive Hepatitis C Interview: Daryl Luster

So my first question is, can you please tell me a little bit about yourself? DARYL LUSTER: Oh, gosh, what’s to tell? I’m 61 this month. Regarding my background, if somebody had said to me 10, even 15 years ago, that I would be involved in health advocacy, I would have said, huh?  No. Really? So it’s been a real shift for me. I come from a business ...

Read More


Exclusive HCV Interview: Lucinda K Porter, RN

Please tell me a little bit about yourself. LUCINDA: I was a patient who was infected with hepatitis C in 1988, and I turned that into an opportunity to learn more about hepatitis C. I have been working in this field since 1997. Along the way, I worked at Stanford Medical Center in their Hepatology Division. I’ve also done a lot of writing since the late ’90s, ...

Read More


Decentralized HCV Treatment is Effective!

Given the safety, tolerability, simplicity, and efficacy of hepatitis C direct-acting antiviral (DAA) regimens, decentralizing treatment from gastroenterologists and hepatologists to other specialists, community-based primary care physicians, or appropriately supervised mid-level providers (ie, task-shifting) may be an effective strategy to increase treatment rates, ...

Read More


HCV Drug Costs: A Treatment Access Barrier

In a newly published, thought-provoking article in the journal Clinical Infectious Diseases, Stacey B. Trooskin and colleagues discuss how the high cost of newer hepatitis C therapies has become a major treatment access barrier in the US (Trooskin SB, et al. Clin Infect Dis. 2015 Aug 12 [Epub ahead of print]). Controversial insurance coverage restrictions and ...

Read More


GS-5816: a DAA with pan-genotypic HCV activity

The availability of a safe, highly effective, pangenotypic regimen for the treatment of HCV infection would have a major impact on global disease prevalence, as it would be suitable for treatment of all infected persons regardless of genotype. Results of a new phase 1 study demonstrate the safety and potent pan-genotypic HCV activity of GS-5816, a novel inhibitor of ...

Read More


Addressing the Restricted Use of DAA therapies

Results of a new US cost effectiveness study indicate that effective direct acting antiviral (DAA) therapies should be not be restricted to only those HCV-infected patients with advanced fibrosis. Authors note that as a society, we have an opportunity to eliminate hepatitis C by taking appropriate and timely steps, and we should be willing to pay for the current HCV ...

Read More


Interventions in the HCV care continuum

New systematic review in the journal International Journal of Drug Policy discusses published evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum. Authors note that primary care settings represent key opportunities for HCV care linkage interventions, often within clinics that have prolonged engagement ...

Read More


Barriers to Accessing HCV Therapies in the US

Recent study indicates that newly available, interferon-free HCV therapies will significantly increase access to care for HCV infected individuals in the US, as unlike standard interferon-based therapies, interferon-free therapies are associated with minimal contraindications. However, a large proportion of US individuals with chronic hepatitis C infection ...

Read More


Special Interview on HCV: Dr. S. Wiktor of WHO

Thank you for agreeing to participate in this special interview on HCV. What do you see as the biggest global challenges in the diagnosis, screening, and treatment of hepatitis C? Dr. Wiktor: The landscape is changing very quickly and it is being driven by remarkable progress in the development of direct-acting antiviral therapies for hepatitis C. We hear ...

Read More